Results 61 to 70 of about 7,605 (170)

Mechanisms of resistance to macrophage checkpoint inhibitors in B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, EarlyView.
Zachary Hunzeker, Francisco Javier de la Rosa, Andrey Tyshevich, Darya Shavronskaya, Julia Alesse, Noel English, Lizzie Sheehan, Nikita Syzrantsev, Alexander Nesmelov, Hans‐Guido Wendel, Paolo Strati   +10 more
wiley   +1 more source

Ferrichrome identified from induces apoptosis through its iron-binding site in gastric cancer cells

Tumor Biology, 2017
Ferrichrome is known to be a siderophore, but it was recently identified as a tumor-suppressive molecule derived from Lactobacillus casei ATCC334 ( L. casei ). In the present study, we investigated the effects of ferrichrome in gastric cancer cells. Cell
Masami Ijiri, Mikihiro Fujiya, Hiroaki Konishi, Hiroki Tanaka, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Junpei Sasajima, Katsuya Ikuta, Toshikatsu Okumura   +9 more
doaj   +1 more source

The Role of N6‐Methyladenosine Modification in Health and Disease

MedComm, Volume 7, Issue 6, June 2026.
N6‐methyladenosine (m6A) is the most prevalent internal RNA modification in eukaryotes, acting as a pivotal epitranscriptomic regulator of RNA metabolism. This modification plays a dual role: it maintains physiological homeostasis under normal conditions but drives disease progression when dysregulated.
Linghuan Li, Yuanhai Sun, Wanfang Zheng, Lingqin Li, Yaqian Feng, Minyou Qi, Hanbing Li   +6 more
wiley   +1 more source

NAD+‒circadian rhythm coupling in dementia

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract The circadian rhythm system and sleep coordinate whole‐body functions across the 24‐h cycle, yet these rhythms progressively deteriorate with neurodegenerative diseases, including dementia. Growing evidence indicates that nicotinamide adenine dinucleotide (NAD+) interacts with the circadian system through multiple molecular pathways and that ...
Shi‐qi Zhang, Jiyeon Lee, Jun‐ping Pan, Rune Enger, Harald Hrubos‐Strøm, Erik S. Musiek, Evandro Fei Fang, Weidong Le   +7 more
wiley   +1 more source

Management of HER2-Low Metastatic Breast Cancer: A Comprehensive Statement by an Expert Group from the Middle East and Africa Region [PDF]

Middle East Journal of Cancer
Approximately 50 to 67% of breast cancers (BCs), traditionally categorized as human epidermal growth factor receptor 2 (HER2)-negative, but demonstrating low HER2 expression, are now being defined as a new HER2-low subset or HER2-low category of BC.
Shaheenah Dawood, Mohsen Mokhtar, Ahmed Alwbari, Bernardo Rapoport, Ece Esin, Hassan Jaafar, Jamal Zekri, Narjiss Berrada, Ozgur Ozyilkan, Nagi El Saghir   +9 more
doaj   +1 more source

Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α‐Positive Advanced Ovarian Cancer

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Folate receptor α (FRα) is a glycosylphosphatidylinositol‐anchored protein that facilitates folate transport and has emerged as a promising therapeutic target for ovarian cancer, particularly due to its association with tumor progression.
Yongsheng Li, Li Yuan, Ge Lou, Hongbing Cai, Yuzhi Li, Fenghu Li, Li Wang, Xingtao Long, Yi Gong, Chaonan Zhu, Li Li, June Xu, Qi Zhou   +12 more
wiley   +1 more source

Exploring alternatives to tumor tissue for BRCA1/2 next‐generation sequencing testing in high‐grade serous ovarian cancer: A 34‐case series of malignant ascites

Cancer Cytopathology, Volume 134, Issue 5, May 2026.
Abstract Background BRCA1/2 testing is currently recommended at diagnosis for high‐grade serous ovarian carcinoma (HGSOC) because of its impact on patients' survival when treated with poly(adenosine diphosphate ribose) polymerase inhibitors. Standard clinical practice involves analyzing BRCA1/2 genes in formalin‐fixed, paraffin‐embedded (FFPE ...
Chiara Pighi, Giulio Settanni, Marta Angelini, Laura Bortesi, Valeria Viassolo, Marcello Ceccaroni, Francesco Bruni, Stefania Gori, Gian Franco Zannoni, Anna Pesci   +9 more
wiley   +1 more source

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?

Medicines, 2020
Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) represent an effective therapeutic strategy for cancer patients harboring germline and somatic aberrations in DNA damage repair (DDR) genes.
Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, Nastassja Tober, Andrea Palloni, Veronica Mollica, Ilaria Maggio, Marzia Deserti, Simona Tavolari, Giovanni Brandi   +9 more
doaj   +1 more source

Purification and properties of poly(adenosine diphosphate ribose) synthetase.

Journal of Biological Chemistry, 1977
Poly(ADP-ribose) synthetase has been purified approximately 5000-fold from rat liver nuclei. The activity of the purified enzyme is absolutely dependent upon the presence of native or synthetic DNA, and the further addition of histone(s) stimulates the activity 3- to 5-fold.
H, Okayama, C M, Edson, M, Fukushima, K, Ueda, O, Hayaishi   +4 more
openaire   +2 more sources

Dietary Ergothioneine as a Novel Anti‐Aging Nutraceutical: Mechanisms, Bioavailability, and Future Perspectives

Food Frontiers, Volume 7, Issue 3, May 2026.
ABSTRACT Ergothioneine (EGT), a natural thiol derivative, has gained attention as a geroprotective nutraceutical. Preclinical research shows EGT scavenges free radicals, maintains mitochondrial integrity, slows telomere erosion, and regulates proteostasis via autophagy and senescent cell clearance.
Tian‐Tian Tian, Liang Chen, Zhen‐Zhen Dong, Chao Yang   +3 more
wiley   +1 more source